Our own highly specialized Health Team, comprised of four PhD professionals, are currently conducting research on stem cells. The intention is to deliver a solid review of facilities, techniques, and future possibilities—consistent with our belief that profitable investments are based on not only unique insight but also good intentions.

Royalton Investment recently invested in a Silicon Valley start-up, providing high-end healthcare solutions. Based on market trends, we believe this investment will be highly profitable, and continue to look for opportunities to seize on the border between technology and health care.